CTRI/2009/091/000821已完成1 期
A Randomized, Double-Blind, Placebo Controlled Study To Assess the Safety And Tolerability Of RotaVac Vaccine (Live Attenuated Bovine-Human (UK) Reassortant Pentavalent Rotavirus Vaccine)
Serum Institute of India Pune India0 个研究点目标入组 114 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 114
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •The subjects will be enrolled in the study, if they meet all the following criteria:
- •(1) Healthy adult male and female subjects aged between 18-45 years and normal Body Mass Index (18.5 to 24.9 kg/m2) with minimum of 50 kg weight (for Group I); (2) Healthy toddlers male and female subjects aged between 2-5 years and normal weight for age (for Group II); (3) Healthy infants male and female subjects aged between 8-10 weeks of age at the time of vaccination and are born with more than 37 week gestation and birth weight 2500 gm or above (for Group III); (4) Normal health as determined by medical history, clinical examination and laboratory assessment; (5) Subjects or parent/guardian of subjects willing to adhere to the protocol requirements and to provide written informed consent; (6) Subjects or parent/guardian of subjects will be available for the follow-up throughout the study period; (7) Has Access to telephone at home or in the immediate neighbourhood; (8) Normal 12-lead electrocardiogram (ECG) and chest X-Ray (PA view) (for Group I); (9) Female subjects who are either currently using reliable methods of birth control, have a negative pregnancy test during screening & prior to vaccine administration and agree to avoid pregnancy during participation in the study (for Group I); (10) Negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, marijuana, cocaine, and morphine) (for Group I).
排除标准
- •The subjects will not be enrolled in the study, if they meet any of the following criteria:
- •(1) Prior receipt of any rotavirus vaccine; (2) Fever at time of immunisation; (3) History of diarrhoea or blood in stool or abnormal stool pattern in past one week; (4) A known sensitivity or allergy to any components of the study medication; (5) History or presence of asthma, urticaria or other allergic reaction; (6) History of chronic gastrointestinal disease, intussusceptions, gastrointestinal malformation or abdominal surgery; (7)
- •Presence of any significant systemic disorder (cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological, cancer or autoimmune disease) which would endanger the subjects health or is likely to result in non conformance to the protocol; (8)
- •Major congenital or genetic defect; (9) Has received immunosuppressant for more than 14 days or other immune-modifying drugs; (10) Has any confirmed or suspected immunosuppressive or immunodeficiency condition; (11)
- •Household contact with an immunosuppressed individual or pregnant woman; (12) Has received any immunoglobulin therapy or blood products prior to start of study; (13) Use of any investigational or non-registered drug other than the study vaccine(s) within 30 days preceding the first dose of the study vaccine or placebo, or planned use during the study period; (14)
- •Subjects participating in any other clinical trial; (15) Participation in a drug research study within past 3 months; (16) Subject is not suitable for inclusion in the study in the opinion of the investigator; (17) Investigator site personnel directly affiliated with this study and their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted; (18) Blood donation within the last 3 months (for Group I); (19) History or presence of significant alcoholism or drug abuse in the past one year (applicable to adults) (for Group I); (20) Subject have received any other vaccine within the past 7 days preceding the study vaccine administration.
研究者
相似试验
进行中（未招募）
1 期
A study in which the safety and efficacy of Nefecon is compared with placebo in patients with primary IgA Nephropathy.Primary IgA nephropathy patients at risk of developing end stage renal diseaseMedDRA version: 20.0Level: LLTClassification code 10069341Term: Berger's diseaseSystem Organ Class: 100000004857EUCTR2017-004902-16-FICalliditas Therapeutics AB360
已完成
2 期
A Randomized, Double-Blind, Placebo Controlled Study to Assess Safety and Tolerability of RotaVac Vaccine (Live Attenuated Bovine-Human (UK) Reassortant Pentavalent Rotavirus Vaccine)CTRI/2010/091/003064Serum Institute of India Ltd60
进行中（未招募）
1 期
A Study of Venetoclax Co-Administered with Low Dose Cytarabine Versus Low Dose Cytarabine in Untreated Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive ChemotherapyAcute Myeloid LeukemiaEUCTR2016-003900-30-ESAbbVie Deutschland GmbH & Co. KG175
进行中（未招募）
1 期
A study in which the safety and efficacy of Nefecon is compared with placebo in patients with primary IgA Nephropathy.Primary IgA nephropathy patients at risk of developing end stage renal diseaseMedDRA version: 20.0Level: LLTClassification code 10069341Term: Berger's diseaseSystem Organ Class: 100000004857EUCTR2017-004902-16-ESCalliditas Therapeutics AB450
进行中（未招募）
1 期
Study of COR388 in Subjects with Alzheimer’s DiseaseAlzheimer’s DiseaseMedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852EUCTR2019-000370-27-GBCortexyme, Inc.573